NCT05452499

Brief Summary

Introduction: Breast cancer represents the most common type of malignant neoplasm worldwide. Advances in diagnosis and treatment have increased the life expectancy of patients. However, the sequelae associated with treatment and disease in survivors such as chronic pain, kinesiophobia and loss of physical function represent a long-term health problem. Physical therapy is a frequently used strategy for the treatment of sequelae in the acute stage of the disease, but there is a need to evaluate its effectiveness in cancer survivors with chronic sequelae. Therapeutic exercise and pain neuroscience education have been shown to be effective in the management of populations with chronic pain and loss of function; however, more evidence is needed in specific populations of cancer survivors. Objective:To evaluate the effectiveness of a physical therapy program based on pain neuroscience education and therapeutic exercise for the treatment of chronic pain, kinesiophobia and loss of physical function in breast cancer survivors. Methodology. Quasi-experimental study. The sample will consist of 40 female breast cancer survivors. The intervention will last 9 weeks, with 3 sessions of pain neuroscience education and 24 sessions of therapeutic exercise, 3 times per week (16 face-to-face sessions and 8 sessions at home). The intervention will be carried out in small groups of 8 to 12 people. The frequency and intensity of pain, the level of kinesiophobia and physical functionality and the range of of motion of the shoulder will be evaluated in 4 assessments, before the intervention (T0), 3rd (T1), 6th (T2) and 9th (T3) week of the intervention. Different validated measurement instruments will be used in this population such as self-report scales, questionnaires and the use of a goniometer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
26

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 6, 2022

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 11, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

September 5, 2022

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 9, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 9, 2023

Completed
Last Updated

March 28, 2023

Status Verified

March 1, 2023

Enrollment Period

4 months

First QC Date

July 6, 2022

Last Update Submit

March 24, 2023

Conditions

Keywords

Breast neoplasmsBreast cancer survivorsChronic painPainKinesiophobiaPain neuroscience educationExercise

Outcome Measures

Primary Outcomes (2)

  • Changes in pain intensity

    Pain intensity will be measured using the visual analog scale (VAS), participants will report their pain intensity within a range of 0 to 100 millimeters, with 0 being no pain and 100 being the maximum pain.

    Four evaluations will be performed, before the intervention (T0) and at the 3rd (T1), 6th (T2) and 9th (T3) week of the physiotherapy program.

  • Changes in pain frequency

    Participants will report the number of days per week with pain.

    Four evaluations will be performed, before the intervention (T0) and at the 3rd (T1), 6th (T2) and 9th (T3) week of the physiotherapy program.

Secondary Outcomes (3)

  • Changes in kinesiophobia

    Four evaluations will be performed, before the intervention (T0) and at the 3rd (T1), 6th (T2) and 9th (T3) week of the physiotherapy program.

  • Changes in physical functionality

    Four evaluations will be performed, before the intervention (T0) and at the 3rd (T1), 6th (T2) and 9th (T3) week of the physiotherapy program.

  • Shoulder range of motion

    Four evaluations will be performed, before the intervention (T0) and at the 3rd (T1), 6th (T2) and 9th (T3) week of the physiotherapy program.

Other Outcomes (4)

  • Personal characteristics

    This data will be recollected only before the intervention (T0).

  • Evaluation of neuropathic and nociceptive type of pain

    Four evaluations will be performed, before the intervention (T0) and at the 3rd (T1), 6th (T2) and 9th (T3) week of the physiotherapy program.

  • Central sensitization

    Four evaluations will be performed, before the intervention (T0) and at the 3rd (T1), 6th (T2) and 9th (T3) week of the physiotherapy program.

  • +1 more other outcomes

Study Arms (1)

Intervention group

EXPERIMENTAL
Other: Pain neuroscience education and therapeutic exercise

Interventions

Participants will receive a 9-week physiotherapy program. Consisting of 3 sessions of pain neuroscience education and 24 sessions of therapeutic exercise (16 face-to-face sessions and 8 at home).

Intervention group

Eligibility Criteria

Age25 Years - 65 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Have had a stage I to III diagnosis.
  • Report a pain intensity of 30 millimeters or more in the Visual Analoge Scale (VAS).
  • Be in completed remission and have completed primary treatment at least three months age. Adjuvant hormone therapy or inmunotherapy is accepted.
  • Present pain in the neck, arms or shoulder of the affected side after primary cancer treatment, and that is repeated or maintained for a period longer than three months.
  • Presenting kinesiophobia measured with the Tampa Scale for Kinesiophobia (TSK-11V).
  • That presents alterations in the physical functionality of the upper limb, measured with the Upper Limb Functional Index (ULFI-Sp).
  • Who is willing to participate through informed consent.
  • \. Due to the current health situation in a state of pandemic by COVID-19, the patient must have their full COVID-19 vaccination.

You may not qualify if:

  • That presents some other type of cancer or metastasis at the time of the study.
  • Have uncontrolled lymphedema or uncontrolled hypertension.
  • That presents a musculoskeletal pathology in the upper limb or a chronic health condition that limits the performance of the therapeutic exercise.
  • Difficulty understanding the Spanish language that limits the comprehension of the evaluation instruments or participating in the pain neuroscience education program.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jose Antonio Lores Peniche

Mérida, Yucatán, 97000, Mexico

Location

MeSH Terms

Conditions

Breast NeoplasmsChronic PainKinesiophobiaPainMotor Activity

Interventions

Exercise Therapy

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPhobic DisordersAnxiety DisordersMental DisordersBehavior

Intervention Hierarchy (Ancestors)

RehabilitationAftercareContinuity of Patient CarePatient CareTherapeuticsPhysical Therapy Modalities

Study Officials

  • Jose Antonio Lores, PT

    Universidad Autónoma de Yucatán

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 6, 2022

First Posted

July 11, 2022

Study Start

September 5, 2022

Primary Completion

January 9, 2023

Study Completion

January 9, 2023

Last Updated

March 28, 2023

Record last verified: 2023-03

Locations